Skip to content

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Oct 2026

Serial circulating tumour DNA monitoring in first-line advanced NSCLC (COPE): a randomized, two-arm non-comparative phase II trial.

PURPOSE COPE evaluated serial circulating tumor DNA (ctDNA) profiling with molecular tumor board (MTB) review during first-line therapy for advanced non-small cell lung cancer (NSCLC). EXPERIMENTAL DESIGN COPE was a multicenter, randomized (2:1), noncomparative phase II trial. Arm A underwent serial plasma profiling...

Candice Francheska B. Tambaoan, Letuan Phan, S. Cousin et al. · 0 citations
Open access Oct 2026

AB008. Final analysis from PECATI phase 2 trial: lenvatinib in combination with pembrolizumab in pretreated advanced B3-thymoma and thymic carcinoma

Background There is no standard second-line treatment for patients with platinum refractory advanced B3-Thymoma (T) and thymic carcinoma (TC). In this population, the PECATI trial testing lenvatinib plus pembrolizumab met its primary endpoint, with 5-month progression-free survival (PFS) of 88.0% (90% CI: 73.5–94.8). M...

Jordi Remon, Paolo Bironzo, Nicolas Girard et al. · 0 citations
Open access Oct 2026

Spatial transcriptomics identifies tumor-intrinsic and stromal programs associated with immune exclusion in NSCLC

It is shown that spatial CD8+ T-cell exclusion is associated with lower objective response rates and shorter progression-free survival in ICB-treated NSCLC patients, and further evaluation of spatial immune contexture as a complementary biomarker in ICB-treated patients is supported.

J. Guégan, B. Bonhomme, F. Peyraud et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.